17Indexed trials
mesh condition
Depressive Disorder, Treatment-Resistant
Intelligence
Depressive Disorder, Treatment-Resistant intelligence: 17 indexed trials, 4 recruiting studies, 15 sponsors across 8 countries.
4Recruiting
15Sponsors
8Countries
Leading sponsors
Massachusetts General Hospital20 recruiting
Charite University, Berlin, Germany20 recruiting
Jonathan A. Javitch, MD, PhD10 recruiting
Jordan F. Karp10 recruiting
ReST Therapeutics10 recruiting
Relmada Therapeutics, Inc.10 recruiting
Rupert Lanzenberger10 recruiting
University Hospital Freiburg10 recruiting
University of Calgary10 recruiting
University of Greifswald11 recruiting
University of Oxford10 recruiting
Università Vita-Salute San Raffaele11 recruiting
Geographic activity
United States6trials
Germany4trials
Canada2trials
United Kingdom2trials
Belgium1trials
Australia1trials
Italy1trials
Austria1trials
Leading interventions
Esketamine 56 mg1trials
Esketamine 84 mg1trials
Fluoroethylnormemantine (FENM)1trials
Ketamine Hydrochloride1trials
Low Field Magnetic Stimulation (LFMS)1trials
Medtronic Activa SC DBS, Lead Model 33871trials
Minocycline1trials
Olanzapine1trials
Omega 31trials
PF-049952741trials
Placebo Oral Tablet1trials
DBS of Cg251trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.